$13,931.24 consulting Payment -- Johnson & Johnson to Dr. Stephanie King

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report details a payment of $13,931.24 made by Johnson & Johnson to Dr. Stephanie King, a General Surgeon in City, MN, on December 12, 2024. The payment was for consulting services related to Ozempic. Consulting fees can involve a range of activities, such as providing expert advice on drug development, clinical trial design, or marketing strategies. The amount, while substantial, is not necessarily unusual for specialized consulting work in the pharmaceutical industry, especially for physicians with significant expertise. However, any payment from a drug manufacturer to a physician warrants careful consideration regarding potential conflicts of interest. While Dr. King's specialty is General Surgery, Ozempic is primarily used for managing type 2 diabetes and weight loss, conditions often managed by endocrinologists or primary care physicians. It's possible Dr. King's consulting role relates to surgical aspects of diabetes management or bariatric surgery, or perhaps she has a broader scope of practice or advisory role. The Sunshine Act requires manufacturers to report these payments, promoting transparency. This specific payment is above the reporting threshold. Patients should understand that such relationships, while legal and regulated, can create an appearance of bias. It's crucial for patients to have open conversations with their doctors about any financial ties to pharmaceutical companies to ensure their treatment decisions are based solely on their best medical interests. This payment, by itself, does not indicate that Dr. King's prescribing decisions are compromised, but it highlights the importance of ongoing transparency and patient awareness.

Patient Guidance: What This Payment Means for You

It's understandable to feel concerned when you see payments between pharmaceutical companies and your doctor. This payment of $13,931.24 to Dr. King from Johnson & Johnson for consulting on Ozempic is a significant amount. While consulting is a legal and regulated activity, it's important to consider how it might influence care. Ozempic is primarily for diabetes and weight management, so understanding why a general surgeon is consulting on it is key. Don't hesitate to ask Dr. King directly at your next appointment: 'I saw you received a consulting payment from Johnson & Johnson regarding Ozempic. Can you explain what that involved and how it relates to my care?' This opens a dialogue. Routine payments for speaking or consulting are common, but large or frequent payments, especially for drugs outside a doctor's primary specialty, might warrant closer attention. The key is open communication to ensure your treatment plan is always based on your health needs, not industry influence.

Payment Context: Is This Amount Normal?

Payments for consulting services to physicians can vary widely based on specialty, expertise, and the nature of the consultation. For specialized medical advice, amounts like $13,931.24 are within the range of what pharmaceutical companies might pay for expert input. While many physicians in General Surgery may not receive such direct consulting payments, a portion do engage in these activities. The frequency and amount can differ significantly from physician to physician within the same specialty.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, mandates that pharmaceutical and medical device companies report payments and other transfers of value made to physicians and teaching hospitals. This payment, exceeding the reporting threshold, was publicly disclosed on the CMS Open Payments database. These disclosures are intended to increase transparency and allow patients to be aware of potential financial relationships between healthcare providers and industry. Such payments are subject to reporting but not necessarily special scrutiny unless specific violations of anti-kickback statutes are suspected.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• sunshine-act
• consulting-fees
• ozempic
• general-surgery
• conflict-of-interest
• transparency

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can check if your doctor receives payments from pharmaceutical or medical device companies through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This database, mandated by the Sunshine Act, lists reported payments made to physicians. Searching by your doctor's name and NPI (National Provider Identifier) will reveal any disclosed financial relationships. Seeing payments doesn't automatically mean your doctor's decisions are compromised, but it's valuable information for understanding potential influences and fostering open communication about your care.

Should I worry about this payment?

This specific payment of $13,931.24 from Johnson & Johnson to Dr. King for consulting on Ozempic is a significant amount. While consulting is a legitimate activity, the amount and the drug's primary use (diabetes/weight loss) compared to the doctor's specialty (General Surgery) might raise questions. It's not necessarily cause for alarm, as Dr. King might have specific expertise relevant to the drug's application or development. However, it's a good reason to have an open conversation with your doctor about their relationship with the company and how it impacts your care decisions.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that are large, frequent, or tied directly to prescribing specific drugs without clear justification. This includes 'speaker fees' for promotional talks, 'consulting fees' for advisory boards, or 'research grants' where the physician has significant financial interest. Payments for meals, travel, or gifts, while smaller, can also create subtle biases. Payments for genuine research, education, or advisory roles that are transparently disclosed and clearly beneficial to patient care are generally less concerning than those that appear to reward prescribing habits.

How do I talk to my doctor about pharma relationships?

Start by stating what you've observed: 'I noticed on the Open Payments website that you received a payment from [Company Name] for [Reason].' Then, ask open-ended questions like: 'Can you tell me more about that relationship?' or 'How does that relationship influence the treatment options you consider for me?' Express your desire for transparency: 'I want to be sure my treatment is based solely on what's best for my health.' A doctor who is open and willing to discuss these relationships is a positive sign. If they become defensive, it might warrant further consideration.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments comply with federal laws like the Anti-Kickback Statute and the Physician Payments Sunshine Act. The Sunshine Act requires companies to publicly report most payments made to physicians and teaching hospitals, promoting transparency. These payments can be for legitimate services like consulting, speaking, research, or serving on advisory boards. The legality hinges on the payment being for bona fide services and not an inducement to prescribe or recommend specific products.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns. Even small payments, like meals, have been linked to increased prescribing of the company's drugs. Larger payments for consulting or speaking may have a more pronounced effect. While not all doctors are influenced, the potential for bias exists. Transparency through the Sunshine Act allows patients to be aware of these relationships, empowering them to discuss treatment options openly with their doctors and ensure decisions are patient-centered.

How does this compare to other doctors in this specialty?

The CMS Open Payments data allows for comparisons. While specific averages fluctuate, a significant percentage of physicians across various specialties receive payments. For General Surgery, the proportion and average amounts can vary. A $13,931.24 consulting fee is a substantial payment, potentially placing Dr. King above the average for physicians who receive any payments, but it's crucial to know if this is a one-time engagement or a pattern. Many physicians in this field do not receive such direct consulting payments, while others engage more frequently.

Related Reports

• View Dr. Stephanie King's full payment report
• Johnson & Johnson full spending report
• Browse all General Surgery payments
• Browse all payments in Minnesota
• Search for other payments